Vaxcyte (PCVX) Total Liabilities (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Total Liabilities of $352.3 million for Q1 2026, up 97.83% year-over-year from $178.1 million in Q1 2025, and up 11.06% quarter-over-quarter from $317.2 million in Q4 2025.
Vaxcyte (PCVX) Total Liabilities (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Total Liabilities for 8 consecutive years, with $352.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 97.83% year-over-year to $352.3 million; the TTM figure through Mar 2026 stood at $352.3 million (up 97.83% YoY), while the FY2025 annual figure was $317.2 million, up 54.36% from the prior year.
- Total Liabilities improved to $352.3 million in Q1 2026 per PCVX's latest filing, from $317.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $352.3 million in Q1 2026 and bottomed at $43.2 million in Q1 2022.
- Historically, Total Liabilities has averaged $147.3 million across 5 years, with a median of $107.3 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities declined 22.09% — and 2023, when it surged 218.56%.
- Vaxcyte's Total Liabilities stood at $52.6 million in 2022, then soared by 218.56% to $167.4 million in 2023, then grew by 22.72% to $205.5 million in 2024, then jumped by 54.36% to $317.2 million in 2025, then grew by 11.06% to $352.3 million in 2026.
- Business Quant data shows PCVX's Total Liabilities at $352.3 million in Q1 2026, $317.2 million in Q4 2025, and $278.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 380.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 380.21 Mn |
| Mar 31, 2026 | 352.29 Mn |
| Dec 31, 2025 | 317.21 Mn |
| Sep 30, 2025 | 278.72 Mn |
| Jun 30, 2025 | 234.03 Mn |
| Mar 31, 2025 | 178.08 Mn |
| Dec 31, 2024 | 205.50 Mn |
| Sep 30, 2024 | 142.11 Mn |
| Jun 30, 2024 | 101.14 Mn |
| Mar 31, 2024 | 107.32 Mn |
| Dec 31, 2023 | 167.45 Mn |
| Sep 30, 2023 | 93.34 Mn |
| Jun 30, 2023 | 69.44 Mn |
| Mar 31, 2023 | 63.39 Mn |
| Dec 31, 2022 | 52.57 Mn |
| Sep 30, 2022 | 52.75 Mn |
| Jun 30, 2022 | 45.12 Mn |
| Mar 31, 2022 | 43.17 Mn |
| Dec 31, 2021 | 40.32 Mn |
| Sep 30, 2021 | 48.11 Mn |